Outsourcing of drug discovery Outsourcing saves time, cost, and efforts of pharmaceutical and biological companies.

TMR estimates that the global market for inflammatory bowel disease would expand at a sluggish CAGR of 2.60% over the period between 2017 and 2025.

The global pneumococcal vaccines market is segmented into distribution channel, product type, and region. Based on the product type, the market is divided into 10- valent PCV, 7- valent PCV, 13- valent PCV, and 23- valent PPSV.

Expanding at a CAGR of 6.4% between 2017 and 2025, the market is likely to be worth US$3,044.8 mn by the end of 2025.

Prominent names in the global antacids market include AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Pfizer Inc., Reckitt Benckiser Group plc, Sun Pharmaceuticals Ltd.

TMR has prophesied the Europe neurological disorder drugs market to rise at a 6.4% CAGR during the forecast tenure 2016-2024. By the completion of the forecast tenure, the market could be valued at a US$32.0 bn.

Domain experts at TMR prognosticate the global homeopathy product market to make a drastic progress during the forecast tenure 2016-2024 at an 18.2% CAGR

According to Transparency Market Research, the U.S. bacterial conjunctivitis drugs market will be worth US$439.8 mn by 2024.